For younger patients with an acute lymphoblastic leukemia (ALL) subtype, modifying treatment based on chemotherapy response can make a vital difference.
Results of a phase I clinical trial showed that a new drug targeting mitochondrial function in human cancer cells was safe and showed some efficacy in a heavily pretreated cohort of patients.
Tyrosine kinase inhibitors (TKIs) may be effective for the treatment of acute lymphoblastic leukemia (ALL).
Many young adults with the most common form of acute lymphoblastic leukemia (ALL) have a high-risk subtype with a poor prognosis and could benefit from drugs used to treat other types of leukemia.
Weekend hospital admission for pediatric patients with newly diagnosed leukemia is associated with a longer length of stay, slightly longer wait to start chemotherapy, and higher risk for respiratory failure.
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|